Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT

BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US HQ
103 Employees
Public company Type
BBOT · NYSE Ticker
Company details
Status
Public
HQ
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
Employees
103
Programs
34
Drugs
14
Patents
1
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BridgeBio Oncology Therapeutics projects

12 ClinicalTrials.gov programs sponsored by BridgeBio Oncology Therapeutics.

BridgeBio Oncology Therapeutics has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

12 programs

Clinical programs

  1. AG10

    BridgeBio Oncology Therapeutics

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  2. ALXN2060

    BridgeBio Oncology Therapeutics

    Symptomatic Transthyretin Amyloid Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  3. Acoramidis

    BridgeBio Oncology Therapeutics

    Amyloidosis

    phase 3 small molecule active

    3 trials

  4. Acoramidis

    BridgeBio Oncology Therapeutics

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  5. Acoramidis (AG10)

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 3 small molecule active

    1 trial

  6. Acoramidis (AG10)

    BridgeBio Oncology Therapeutics

    Amyloidosis in Transthyretin (TTR)

    phase 3 small molecule active

    1 trial

  7. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  8. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia (ADH)

    phase 3 small molecule active

    2 trials

  9. Encaleret

    BridgeBio Oncology Therapeutics

    Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    phase 3 small molecule active

    1 trial

  10. Infigratinib

    BridgeBio Oncology Therapeutics

    Upper Tract Urothelial Carcinomas

    phase 3 small molecule terminated

    1 trial

  11. Infigratinib 0.25 mg/kg/day

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 3 small molecule completed

    1 trial

  12. infigratinib 0.128 mg/kg/day

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does BridgeBio Oncology Therapeutics have?

12 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.